Infigratinib

Infigratinib, sold under the brand name Truseltiq, is an anti-cancer medication used to treat cholangiocarcinoma (bile duct cancer).[1][2][3] Infigratinib is a kinase inhibitor targeting the fibroblast growth factor receptors FGFR1, FGFR2 and FGFR3[4][2][3] It was designated an orphan drug by the U.S. Food and Drug Administration (FDA) in 2019,[5] and it was approved for medical use... [wikipedia]